Cargando…

Gene therapy for colorectal cancer using adenovirus-mediated full-length antibody, cetuximab

Cetuximab is a chimeric monoclonal antibody, approved to treat patients with metastatic colorectal cancer (mCRC), head and neck squamous cell carcinoma (HNSCC), non-small-cell lung cancer (NSCLC) for years. It functions by blocking the epidermal growth factor receptor (EGFR) from receiving signals o...

Descripción completa

Detalles Bibliográficos
Autores principales:	Xing, Man, Wang, Xiang, Chi, Yudan, Zhou, Dongming
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Impact Journals LLC 2016
Materias:	Research Paper
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5053725/ https://www.ncbi.nlm.nih.gov/pubmed/27058423 http://dx.doi.org/10.18632/oncotarget.8596

Ejemplares similares

Neutralizing antibody responses to enterovirus and adenovirus in healthy adults in China
por: Wang, Xiang, et al.
Publicado: (2014)

MicroRNAs in colorectal carcinoma - from pathogenesis to therapy
por: Chi, Yudan, et al.
Publicado: (2016)

A novel oncolytic adenovirus based on simian adenovirus serotype 24
por: Cheng, Tao, et al.
Publicado: (2017)

Survivin-targeting Artificial MicroRNAs Mediated by Adenovirus Suppress Tumor Activity in Cancer Cells and Xenograft Models
por: Chi, Yudan, et al.
Publicado: (2014)

Chimpanzee adenovirus-mediated multiple gene therapy for age-related macular degeneration
por: Wei-Zhang, Selena, et al.
Publicado: (2023)

Adenovirus delivery of encoded monoclonal antibody protects against different types of influenza virus infection
por: Wang, Xiang, et al.
Publicado: (2020)

Mechanism of resistance to cetuximab therapy in colorectal cancer: Possible role of antibodies to immunoglobulin allotypes
por: Pandey, Janardan P.
Publicado: (2012)

Loss of coxsackie and adenovirus receptor expression in human colorectal cancer: A potential impact on the efficacy of adenovirus-mediated gene therapy in Chinese Han population
por: Ma, Ying-Yu, et al.
Publicado: (2016)

The anti-HER3 antibody patritumab abrogates cetuximab resistance mediated by heregulin in colorectal cancer cells
por: Kawakami, Hisato, et al.
Publicado: (2014)

Reovirus activated NK cells show enhanced cetuximab mediated antibody-dependent cellular cytotoxicity against colorectal cancer cells
por: Zhao, Xing, et al.
Publicado: (2015)

Intratumoral delivery of a novel oncolytic adenovirus encoding human antibody against PD-1 elicits enhanced antitumor efficacy
por: Zhou, Ping, et al.
Publicado: (2022)

Cetuximab in the management of colorectal cancer
por: Lenz, Heinz-Josef
Publicado: (2007)

In vivo Recombinant Adenovirus-mediated p53 Gene Therapy in a Syngeneic Rat Model for Colorectal Cancer
por: Baek, Jeong-Heum, et al.
Publicado: (2004)

Detection of genes responsible for cetuximab sensitization in colorectal cancer cells using CRISPR-Cas9
por: Hu, Ting-ting, et al.
Publicado: (2020)

Adenovirus Biology, Recombinant Adenovirus, and Adenovirus Usage in Gene Therapy
por: Watanabe, Maki, et al.
Publicado: (2021)

Prerequisites for effective adenovirus mediated gene therapy of colorectal liver metastases in the rat using an intracellular neutralizing antibody fragment to p21-Ras
por: van Etten, B, et al.
Publicado: (2002)

Cetuximab-Mediated Protection from Hypoxia- Induced Cell Death: Implications for Therapy Sequence in Colorectal Cancer
por: Urban, Hans, et al.
Publicado: (2020)

Enhancing full-length antibody production by signal peptide engineering
por: Zhou, Yizhou, et al.
Publicado: (2016)

Targeting of colorectal cancer organoids with zoledronic acid conjugated to the anti-EGFR antibody cetuximab
por: Benelli, Roberto, et al.
Publicado: (2022)

Cetuximab-based therapy in elderly comorbid patients with metastatic colorectal cancer
por: Jehn, C F, et al.
Publicado: (2012)

Targeting strategies of adenovirus-mediated gene therapy and virotherapy for prostate cancer
por: Cai, Zhonglin, et al.
Publicado: (2017)

A bivalent live-attenuated vaccine candidate elicits protective immunity against human adenovirus types 4 and 7
por: Guo, Jingao, et al.
Publicado: (2021)

Prediction of Target Genes and Pathways Associated With Cetuximab Insensitivity in Colorectal Cancer
por: Yu, Chaoran, et al.
Publicado: (2018)

Evolving role of cetuximab in the treatment of colorectal cancer
por: Schuch, Gunter, et al.
Publicado: (2009)

PRSS contributes to cetuximab resistance in colorectal cancer
por: Tan, Zhaoli, et al.
Publicado: (2020)

Primary resistance to cetuximab therapy in EGFR FISH-positive colorectal cancer patients
por: Cappuzzo, F, et al.
Publicado: (2008)

First-line targeted therapies in the treatment of metastatic colorectal cancer – role of cetuximab
por: Tonini, Giuseppe, et al.
Publicado: (2009)

Lentiviral vectors can be used for full-length dystrophin gene therapy
por: Counsell, John R., et al.
Publicado: (2017)

Lentiviral vectors can be used for full-length dystrophin gene therapy
por: Counsell, John R., et al.
Publicado: (2017)

Review on comparative efficacy of bevacizumab, panitumumab and cetuximab antibody therapy with combination of FOLFOX-4 in KRAS-mutated colorectal cancer patients
por: Pathak, Surajit, et al.
Publicado: (2017)

TRIM21 mediates antibody inhibition of adenovirus-based gene delivery and vaccination
por: Bottermann, Maria, et al.
Publicado: (2018)

PHLDB2 Mediates Cetuximab Resistance via Interacting With EGFR in Latent Metastasis of Colorectal Cancer
por: Luo, Maochao, et al.
Publicado: (2021)

Efficient expression of full-length antibodies in the cytoplasm of engineered bacteria
por: Robinson, Michael-Paul, et al.
Publicado: (2015)

Revisiting oral fluoropyrimidine with cetuximab in metastatic colorectal cancer: Real-world data in Chinese population
por: Lam, Ka-On, et al.
Publicado: (2019)

Pleiotrophin Gene Therapy for Peripheral Ischemia: Evaluation of Full-Length and Truncated Gene Variants
por: Fang, Qizhi, et al.
Publicado: (2013)

Dasatinib sensitizes KRAS mutant colorectal tumors to cetuximab
por: Dunn, Emily F., et al.
Publicado: (2010)

PTEN status in advanced colorectal cancer treated with cetuximab
por: Negri, F V, et al.
Publicado: (2010)

Expression of neurofibromin 1 in colorectal cancer and cetuximab resistance
por: Tak, Eunyoung, et al.
Publicado: (2022)

Maintenance Therapy With Cetuximab After FOLFIRI Plus Cetuximab for RAS Wild-Type Metastatic Colorectal Cancer: A Phase 2 Randomized Clinical Trial
por: Boige, Valérie, et al.
Publicado: (2023)

The cardiotoxicity of cetuximab as single therapy in Chinese chemotherapy-refractory metastatic colorectal cancer patients
por: Tang, Xue-Miao, et al.
Publicado: (2017)

Cannot write session to /tmp/vufind_sessions/sess_19hfc17u06uposdh5lcnck5fut